Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines.
CONCLUSIONS: The results suggest that treatment with sTPs, especially thymosin α1, and concomitant chemotherapy is beneficial to the patient, and provide evidence for optimal treatment regimens that may increase patient QOL and survival.
PMID: 31326719 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Zeng FL, Xiao Z, Wang CQ, Jiang Y, Shan JL, Hu SS, Huang XR, Tang YH, Yao XS, Zhang T, Zeng XT, Feng JH, Xiao X Tags: Int Immunopharmacol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | China Health | Databases & Libraries | Gastroenterology | Lung Cancer | Non-Small Cell Lung Cancer | Study | Thrombocytopenia